头孢他啶-阿维巴坦与美罗培南对泛耐药、产碳青霉烯酶、被研究使用时间杀伤和药敏纸片近似法测定的菌株的协同作用。
Synergistic Effect of Ceftazidime-Avibactam with Meropenem against Panresistant, Carbapenemase-Harboring and Investigated Using Time-Kill and Disk Approximation Assays.
机构信息
Laboratório de Investigação Médica 54 (LIM-54), Instituto de Medicina Tropical, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.
Divisão de Laboratório Central - Serviço de Microbiologia Clínica, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.
出版信息
Antimicrob Agents Chemother. 2019 Apr 25;63(5). doi: 10.1128/AAC.02367-18. Print 2019 May.
Abstract
Susceptibility of ceftazidime-avibactam and synergy with meropenem were investigated using disk approximation and time-kill assays against 11 multiresistant isolates harboring oxacillinases and 5 isolates carrying Ceftazidime-avibactam was very active and synergistic with meropenem against multiresistant isolates. On the other hand, only the isolates coharboring and displayed synergy. The disk approximation technique presented good sensitivity for synergism in infection.
摘要
采用纸片琼脂扩散法和时间杀菌法，检测了头孢他啶-阿维巴坦的药敏性及其与美罗培南的协同作用，共检测了 11 株携带耐甲氧西林酶的多耐药株和 5 株携带头孢他啶-阿维巴坦的耐药株。头孢他啶-阿维巴坦对多耐药株非常有效，并与美罗培南具有协同作用。另一方面，只有同时携带 和 的耐药株显示出协同作用。纸片琼脂扩散法在 感染中对协同作用具有良好的敏感性。
相似文献
1
Synergistic Effect of Ceftazidime-Avibactam with Meropenem against Panresistant, Carbapenemase-Harboring and Investigated Using Time-Kill and Disk Approximation Assays.头孢他啶-阿维巴坦与美罗培南对泛耐药、产碳青霉烯酶、被研究使用时间杀伤和药敏纸片近似法测定的菌株的协同作用。
Antimicrob Agents Chemother. 2019 Apr 25;63(5). doi: 10.1128/AAC.02367-18. Print 2019 May.
2
Activity of Imipenem-Relebactam and Meropenem-Vaborbactam against Carbapenem-Resistant, SME-Producing Serratia marcescens.亚胺培南-雷巴他定和美罗培南-沃诺拉赞对产 SME 碳青霉烯酶耐药黏质沙雷氏菌的活性。
Antimicrob Agents Chemother. 2020 Mar 24;64(4). doi: 10.1128/AAC.02255-19.
3
Effects of KPC Variant and Porin Genotype on the Activity of Meropenem-Vaborbactam against Carbapenem-Resistant .KPC 变体和孔蛋白基因型对美罗培南-沃班坦对碳青霉烯类耐药 的活性的影响。
Antimicrob Agents Chemother. 2019 Feb 26;63(3). doi: 10.1128/AAC.02048-18. Print 2019 Mar.
4
In vitro activities of ceftazidime/avibactam alone or in combination with antibiotics against multidrug-resistant Acinetobacter baumannii isolates.头孢他啶/阿维巴坦单独或联合抗生素对多重耐药鲍曼不动杆菌分离株的体外活性。
J Glob Antimicrob Resist. 2019 Jun;17:137-141. doi: 10.1016/j.jgar.2018.12.004. Epub 2018 Dec 18.
5
In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing .头孢他啶-阿维巴坦对产碳青霉烯酶的. 的体外和体内杀菌活性。
Antimicrob Resist Infect Control. 2018 Nov 21;7:142. doi: 10.1186/s13756-018-0435-9. eCollection 2018.
6
Within-host transition to GES-55 during a GES-6-producing Serratia marcescens outbreak: Emergence of ceftazidime-avibactam resistance and increased susceptibility to carbapenems.在产头孢他啶-阿维巴坦的粘质沙雷氏菌流行期间，宿主内向 GES-55 的转移：头孢他啶-阿维巴坦耐药的出现和对碳青霉烯类药物的易感性增加。
Int J Antimicrob Agents. 2024 Aug;64(2):107257. doi: 10.1016/j.ijantimicag.2024.107257. Epub 2024 Jun 23.
7
Analyses of a Ceftazidime-Avibactam-Resistant Isolate Carrying Reveals a Heterogenous Population and Reversible Genotype.携带 blaOXA-23 基因的头孢他啶-阿维巴坦耐药分离株的分析揭示了一个异质群体和可逆转的基因型。
mSphere. 2018 Sep 26;3(5):e00408-18. doi: 10.1128/mSphere.00408-18.
8
Antimicrobial activities of ceftazidime-avibactam, meropenem-vaborbactam and plazomicin against multidrug-resistant and - a pilot Bulgarian study.头孢他啶-阿维巴坦、美罗培南-巴坦和普拉佐米星对多重耐药菌的抗菌活性——一项保加利亚的试点研究
Infect Dis (Lond). 2019 Nov-Dec;51(11-12):870-873. doi: 10.1080/23744235.2019.1653491. Epub 2019 Aug 21.
9
Activity of Ceftazidime-Avibactam Against Clinical Isolates of Klebsiella pneumoniae, Including KPC-Carrying Isolates, Endemic to New York City.头孢他啶-阿维巴坦对纽约市流行的肺炎克雷伯菌临床分离株（包括携带KPC的分离株）的活性。
Microb Drug Resist. 2018 Jan/Feb;24(1):35-39. doi: 10.1089/mdr.2016.0293. Epub 2017 Jun 7.
10
synergistic activity of the sulbactam/avibactam combination against extensively drug-resistant .舒巴坦/阿维巴坦合剂对广泛耐药的协同活性。
J Med Microbiol. 2020 Jul;69(7):928-931. doi: 10.1099/jmm.0.001211.
引用本文的文献
1
A systematic review and individual bacterial species level meta-analysis of in vitro studies on the efficacy of ceftazidime/avibactam combined with other antimicrobials against carbapenem-resistant Gram-negative bacteria.头孢他啶/阿维巴坦联合其他抗菌药物对耐碳青霉烯革兰氏阴性菌体外抗菌活性的系统评价及单菌属水平的Meta分析
J Antimicrob Chemother. 2025 Feb 3;80(2):334-346. doi: 10.1093/jac/dkae451.
2
Combinations of Antibiotics Effective against Extensively- and Pandrug-Resistant Patient Isolates.对广泛耐药和全耐药患者分离株有效的抗生素组合
Microorganisms. 2024 Jul 2;12(7):1353. doi: 10.3390/microorganisms12071353.
3
Ceftazidime-avibactam combination therapy versus monotherapy for treating carbapenem-resistant gram-negative infection: a systemic review and meta-analysis.头孢他啶-阿维巴坦联合治疗与单药治疗碳青霉烯类耐药革兰氏阴性感染：系统评价和荟萃分析。
Infection. 2024 Oct;52(5):2029-2042. doi: 10.1007/s15010-024-02277-y. Epub 2024 May 13.
4
A Sixty-Nine-Year-Old Female With Serratia marcescens Infection.一名69岁的女性患有粘质沙雷氏菌感染。
Cureus. 2023 Dec 5;15(12):e49985. doi: 10.7759/cureus.49985. eCollection 2023 Dec.
5
In search for a synergistic combination against pandrug-resistant A. baumannii; methodological considerations.针对泛耐药鲍曼不动杆菌的协同组合的寻找：方法学考虑。
Infection. 2022 Jun;50(3):569-581. doi: 10.1007/s15010-021-01748-w. Epub 2022 Jan 4.
6
Quercetin Rejuvenates Sensitization of Colistin-Resistant and Clinical Isolates to Colistin.槲皮素可恢复耐黏菌素菌株及临床分离株对黏菌素的敏感性。
Front Chem. 2021 Nov 25;9:795150. doi: 10.3389/fchem.2021.795150. eCollection 2021.
7
Systematic Review of Antimicrobial Combination Options for Pandrug-Resistant .泛耐药菌抗菌联合治疗方案的系统评价
Antibiotics (Basel). 2021 Nov 3;10(11):1344. doi: 10.3390/antibiotics10111344.
8
Optimal Management of Complicated Infections in the Pediatric Patient: The Role and Utility of Ceftazidime/Avibactam.儿科患者复杂感染的优化管理：头孢他啶/阿维巴坦的作用与效用
Infect Drug Resist. 2020 Jun 12;13:1763-1773. doi: 10.2147/IDR.S209264. eCollection 2020.
9
Molecular Characterization of Carbapenem-Resistant Clinical Isolates in a Tertiary Hospital in Hangzhou, China.中国杭州一家三级医院耐碳青霉烯临床分离株的分子特征分析
Infect Drug Resist. 2020 Apr 7;13:999-1008. doi: 10.2147/IDR.S243197. eCollection 2020.
本文引用的文献
1
Analyses of a Ceftazidime-Avibactam-Resistant Isolate Carrying Reveals a Heterogenous Population and Reversible Genotype.携带 blaOXA-23 基因的头孢他啶-阿维巴坦耐药分离株的分析揭示了一个异质群体和可逆转的基因型。
mSphere. 2018 Sep 26;3(5):e00408-18. doi: 10.1128/mSphere.00408-18.
2
Ceftazidime/avibactam susceptibility by three different susceptibility testing methods in carbapenemase-producing Gram-negative bacteria from Australia.三种不同药敏检测方法在澳大利亚产碳青霉烯酶革兰氏阴性菌中检测头孢他啶/阿维巴坦敏感性。
Int J Antimicrob Agents. 2018 Jul;52(1):82-85. doi: 10.1016/j.ijantimicag.2018.02.017. Epub 2018 Feb 27.
3
In vitro interaction of ceftazidime-avibactam in combination with different antimicrobials against KPC-producing Klebsiella pneumoniae clinical isolates.头孢他啶-阿维巴坦与不同抗菌药物联合对产KPC肺炎克雷伯菌临床分离株的体外相互作用
Int J Infect Dis. 2017 Dec;65:1-3. doi: 10.1016/j.ijid.2017.09.017. Epub 2017 Sep 22.
4
Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?头孢他啶-阿维巴坦和氨曲南能否克服肠杆菌科细菌中金属β-内酰胺酶介导的β-内酰胺耐药性？
Antimicrob Agents Chemother. 2017 Mar 24;61(4). doi: 10.1128/AAC.02243-16. Print 2017 Apr.
5
Ceftazidime-Avibactam as Salvage Therapy for Infections Caused by Carbapenem-Resistant Organisms.头孢他啶-阿维巴坦作为耐碳青霉烯类微生物所致感染的挽救治疗药物
Antimicrob Agents Chemother. 2017 Jan 24;61(2). doi: 10.1128/AAC.01964-16. Print 2017 Feb.
6
Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections.耐碳青霉烯类肠杆菌科细菌感染患者的临床结局、药物毒性及头孢他啶-阿维巴坦耐药性的出现
Clin Infect Dis. 2016 Dec 15;63(12):1615-1618. doi: 10.1093/cid/ciw636. Epub 2016 Sep 13.
7
Antimicrobial Combinations against Pan-Resistant Acinetobacter baumannii Isolates with Different Resistance Mechanisms.针对具有不同耐药机制的泛耐药鲍曼不动杆菌分离株的抗菌药物联合使用
PLoS One. 2016 Mar 21;11(3):e0151270. doi: 10.1371/journal.pone.0151270. eCollection 2016.
8
Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms.头孢他啶-阿维巴坦：一种用于治疗耐药革兰氏阴性菌的新型头孢菌素/β-内酰胺酶抑制剂组合
Clin Ther. 2016 Mar;38(3):431-44. doi: 10.1016/j.clinthera.2016.01.018. Epub 2016 Mar 2.
9
In Vitro Susceptibility to Ceftazidime-Avibactam of Carbapenem-Nonsusceptible Enterobacteriaceae Isolates Collected during the INFORM Global Surveillance Study (2012 to 2014).在INFORM全球监测研究（2012年至2014年）期间收集的碳青霉烯类不敏感肠杆菌科分离株对头孢他啶-阿维巴坦的体外敏感性
Antimicrob Agents Chemother. 2016 Apr 22;60(5):3163-9. doi: 10.1128/AAC.03042-15. Print 2016 May.
10
In vitro activity of ceftazidime/avibactam against Gram-negative pathogens isolated from pneumonia in hospitalised patients, including ventilated patients.头孢他啶/阿维巴坦对住院肺炎患者（包括呼吸机治疗患者）分离的革兰氏阴性病原体的体外活性。
Int J Antimicrob Agents. 2016 Mar;47(3):235-42. doi: 10.1016/j.ijantimicag.2016.01.004. Epub 2016 Feb 3.
Zotero 插件